These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 456403)

  • 1. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man.
    Fuccella LM; Corvi G; Moro E; Pogliani E; Tamassia V; Tosolini G
    Eur J Clin Pharmacol; 1979 Jun; 15(5):323-7. PubMed ID: 456403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man.
    Tamassia V; Corvi G; Fuccella LM; Moro E; Tosolini G; Tremoli E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):329-33. PubMed ID: 456404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
    Vinazzer H; Fuccella LM
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of platelet aggregation in man by indobufen (K 3920).
    Vittoria A; Laghi Pasini F; Messa GL; Di Perri T; Corvi G; Fuccella LM
    J Int Med Res; 1981; 9(1):12-7. PubMed ID: 7202826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of 14C-labelled 2-[p-(1-oxo-2-isoindolinyl)phenyl]butyric acid, (indobufen or K 3920) in blood, platelets and platelet components.
    Vinazzer H; Zolle I; Fuccella LM; Valzelli G
    Thromb Res; 1980 Feb 1-15; 17(3-4):303-16. PubMed ID: 7368166
    [No Abstract]   [Full Text] [Related]  

  • 6. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen.
    Mamiya S; Hagiwara M; Ishikawa T; Hidaka H
    Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dispositional enantioselectivity of indobufen in man.
    Strolm Benedetti M; Frigerio E; Tamassia V; Noseda G; Caldwell J
    Biochem Pharmacol; 1992 May; 43(9):2032-4. PubMed ID: 1596290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of aspirin and indobufen in healthy volunteers.
    Lee JY; Sung KC; Choi HI
    Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM
    Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiaggregant effect of indobufen (K3920) measured by the platelet aggregate filtration pressure test (PAFP).
    Visonà A; Davanzo S; Bruno R; Pagnan A
    J Int Med Res; 1983; 11(1):10-4. PubMed ID: 6832462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excretion balance and urinary metabolites of the S-enantiomer of indobufen in rats and mice.
    Grubb N; Caldwell J; Strolin-Benedetti M
    Biochem Pharmacol; 1993 Oct; 46(8):1507-10. PubMed ID: 8240403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of age on the pharmacokinetics of indobufen.
    Savazzi GM; Castiglioni A; Cavatorta A; Garini G; Montanari M; Borghetti A
    Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):265-9. PubMed ID: 3733275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.
    Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A
    Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen.
    Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I
    J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary studies on indobufen (K 3920). A new inhibitor of platelet aggregation.
    Gürsoy AZ; Yardimci TU; Emekli NB; Ugur MS; Ulutin ON
    Haematologica; 1981 Dec; 66(6):756-67. PubMed ID: 6802717
    [No Abstract]   [Full Text] [Related]  

  • 16. Preliminary human pharmacology studies on the inhibition of platelet aggregation by indobufen (K 3920).
    Pogliani E; Corvi G; Mandelli V; Fuccella LM
    Haematologica; 1981 Apr; 66(2):160-70. PubMed ID: 6115794
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
    Bergamaschi M; Pierucci L; Branzoli U
    Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen.
    Pogliani EM; Colombi M; Cristoforetti G; Valenti G; Miradoli R; Buccianti G
    Pharmatherapeutica; 1982; 3(2):127-32. PubMed ID: 6179101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet aggregation by a new synthetic compound: 2-[p-(1-oxo-2-isoindolinyl)phenyl] butyric acid (K 3920).
    Di Perri T; Vittoria A; Laghi Pasini F
    Arzneimittelforschung; 1979; 29(1):104-6. PubMed ID: 582103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):783-96. PubMed ID: 94870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.